XML 81 R71.htm IDEA: XBRL DOCUMENT v3.19.2
Schedule Of Other Derivatives Not Designated As Hedging Instruments Statements OfFinancial Performance And Financial Position Location (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Net Revenues [Member] | Not Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Gain (Loss) on Derivative Instruments, Net, Pretax $ (4,337) $ (4,701) $ (8,632) $ (9,766)
Net Revenues [Member] | Not Designated as Hedging Instrument, Economic Hedge [Member]        
Derivative [Line Items]        
Gain (Loss) on Derivative Instruments, Net, Pretax 4 (1) 4 (1)
Financial expenses [Member] | Not Designated as Hedging Instrument [Member]        
Derivative [Line Items]        
Gain (Loss) on Derivative Instruments, Net, Pretax 206 236 425 507
Financial expenses [Member] | Not Designated as Hedging Instrument, Trading [Member]        
Derivative [Line Items]        
Gain (Loss) on Derivative Instruments, Net, Pretax [1] $ 34 $ (24) $ (7) $ (5)
[1] Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses—net.